A trial update dated October 7, 2026 reports on a study involving leuprolide as part of neoadjuvant androgen deprivation therapy (ADT). The study, registered as NCT07027124, is titled "Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer."
The trial is listed as a Phase 2 study. Its current status is recruiting, according to the registry entry dated October 7, 2026. The protocol combines neoadjuvant ADT with darolutamide and pembrolizumab, followed by an adjuvant phase using pembrolizumab alone.
Leuprolide is an approved compound commonly used as a form of ADT in prostate cancer treatment protocols. This update reflects only the trial's registration status and design as recorded. No results, efficacy data, or safety findings have been posted for this study at this time.
The trial is described as being conducted in a molecularly stratified population of patients with high-risk prostate cancer, meaning participants may be selected based on specific molecular characteristics. Further details on enrollment criteria and outcome measures are available through the official trial registry listing.
Readers interested in background on this compound can consult the compound overview for additional context.